X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acarizax is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae. It is being evaluated in phase 3 clinical trials for the treatment of house dust mite allergy.
Lead Product(s): Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area: Immunology Product Name: Acarizax
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
ALK Abello AS is developing sublingual immunotherapy (‘SLIT’) tablets and it is under phase 1 clinical development for the treatment of Peanut Allergy.
Lead Product(s): Peanut Sublingual Immunotherapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
ITULAZAX is a sublingual immunotherapy tablet of allergen extract for immunotherapy of tree (birch homologous group) pollen-induced allergic rhinitis and/or conjunctivitis.
Lead Product(s): Birch Pollen Extract
Therapeutic Area: Immunology Product Name: Itulazax
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Odactra (dermatophagoides farinae extract & dermatophagoides pteronyssinus extract) is a prescription medicine used for sublingual immunotherapy to treat house dust mite allergies. ACARIZAX® in Europe and a number of international markets and as MITICURE™ in Japan.
Lead Product(s): Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area: Immunology Product Name: Odactra
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Acarizax® (dermatophagoides farinae extract) is an allergy immunotherapy where repeated administration of allergens to allergic individuals is carried to modify the immunological response to allergen to provide sustained protection during subsequent allergen exposure.
Lead Product(s): Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area: Immunology Product Name: Acarizax
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Odactra (dermatophagoides farinae extract) is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat house dust mite allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes.
Lead Product(s): Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Odactra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
ACARIZAX (dermatophagoides farinae extract)., a HDM SLIT-tablet is a treatment for house dust mite-induced allergic rhinitis with or without conjunctivitis and allergic asthma that is not well controlled by symptomatic medication.
Lead Product(s): Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Acarizax
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2022
Details:
ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
A waiver from Chinese authorities allows ALK to file for regulatory approval in China without finalising its paused local registration trial for ACARIZAX® (HDM SLIT), tablet for treatment of HDM allergic rhinitis for 12-65 year-olds and HDM allergic asthma in 18-65 year-olds.
Lead Product(s): House Dust Mite Allergen Extract
Therapeutic Area: Immunology Product Name: Acarizax
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
Jext® is expected to be the first AAI to market in China. Prior to registration in mainland China, Grandpharma plans to start selling Jext® in southern China under a special licence linked to the existing registration of Jext® in Hong Kong.
Lead Product(s): Epinephrine Bitartrate
Therapeutic Area: Immunology Product Name: Jext
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Grandpharma
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
